Antiglycation and Antioxidant Effect of Carnosine against Glucose Degradation Products in Peritoneal Mesothelial CellsAlhamdani M.-S.S. · Al-Kassir A.-H.A.-M. · Abbas F.K.H. · Jaleel N.A. · Al-Taee M.F.
aDepartment of Medical Sciences, College of Pharmacy, and bDepartment of Internal Medicine, College of Medicine, Al-Mustansiriya University; cArtificial Kidney Unit, Al-Karama Teaching Hospital, dArtificial Kidney Unit, Al-Yarmuk Teaching Hospital, and eBiotechnology Department, College of Sciences, Al-Nahrain University, Baghdad, Iraq
Background/Aim:Toxicity with advanced glycation end products (AGEs) is a major problem in uremic patients. Treatment with peritoneal dialysis (PD) exacerbates AGE formation as a result of bioincompatibility of the conventional peritoneal dialysis fluid (PDF). The presence of glucose degradation products (GDPs) in PDF is the main cause of its bioincompatibility. Carnosine is an endogenous dipeptide with a powerful antiglycation/antioxidant activity. In an attempt to improve PDF biocompatibility, we evaluated the effect of carnosine in human peritoneal mesothelial cells (HPMC) incubated with PDF or GDPs in vitro. Methods: HPMC were incubated for short or prolonged time with PDF in the presence or absence of carnosine. Similarly, HPMC were incubated in the same condition but with a combination of GDPs. Following the incubation, cells were tested for their viability, protein carbonyl content and reactive oxygen species (ROS) production. Results: Results demonstrated a significant protective effect of carnosine to HPMC in both acute and chronic conditions with PDF or GDPs as judged by the enhancement of cell viability, preserved protein from modification and decreased ROS production. Conclusion: Carnosine enhanced HPMC viability against the toxic effect of GDPs probably through protection of cellular protein from modification and from ROS-mediated oxidative damage. The salutary effect of carnosine may render it a desirable candidate for improving PDF biocompatibility and reducing AGE complications in PD patients.
Mohamed-Saiel Saeed Alhamdani
Department of Medical Sciences, College of Pharmacy, Al-Mustansiriya University Dora Highway, Baghdad (Iraq)
Tel. +964 7901 652 459 or +964 7702 751 990
Received: January 5, 2007
Accepted: April 24, 2007
Published online: July 31, 2007
Number of Print Pages : 9
Number of Figures : 6, Number of Tables : 0, Number of References : 45
Nephron Clinical Practice
Vol. 107, No. 1, Year 2007 (Cover Date: September 2007)
Journal Editor: Powis, S.H. (London)
ISSN: 1660–2110 (print), 1660–2110 (Online)
For additional information: http://www.karger.com/NEC